4 patents
Utility
Lasofoxifene Combination Treatment of Er+ Breast Cancer That Has Progressed on a CDK4/6 Inhibitor
30 Nov 23
Methods for reducing the progression of ER+ breast cancer in a patient are provided, the methods comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective amount of a CDK4/6 inhibitor (CDK4/6i), wherein the breast cancer: (i) is estrogen receptor positive (ER+); (ii) has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene; and (iii) has progressed during prior CDK4/6 inhibitor therapy and/or has an oncogenic mutation in a gene other than ESR1.
David J. PORTMAN, Paul PLOURDE, Simon JENKINS
Filed: 25 May 23
Utility
Lasofoxifene Treatment of Aromatase-resistant Er+ Cancer
12 Oct 23
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor.
Barry Samuel KOMM, Geoffrey L. GREENE
Filed: 30 May 23
Utility
Lasofoxifene Treatment of Aromatase-resistant Er+ Cancer
18 May 23
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed on an aromatase inhibitor.
Barry Samuel KOMM, Geoffrey L. Greene
Filed: 17 Nov 22
Utility
Lasofoxifene Treatment of Vva and Osteoporosis In Survivors of Breast Cancer and Other Malignancies
5 May 22
The disclosure provides methods for treating vulvovaginal atrophy (VVA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
David J. PORTMAN
Filed: 7 Sep 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first